NEW ORLEANS--(BUSINESS WIRE)--Optovue, the global leader in the development of optical coherence tomography (OCT) and OCT angiography (OCTA), will highlight its AngioVue® Essential OCTA capability for general ophthalmology, along with its suite of advanced eye care technology at the upcoming American Academy of Ophthalmology Annual Meeting (AAO), Nov. 11-14 in New Orleans.
The company will also host an OCT and OCT Angiography Interpretation Lab offering small group sessions, led by industry experts, for learning the fundamentals of OCTA in retinal disease and glaucoma, as well as epithelial thickness mapping in refractive practice. And, in celebration of three years of OCT Angiography, Optovue will host book signings with Professor Bruno Lumbroso, Dr. David Chow and Dr. David Huang.
“We are thrilled to be celebrating three years since we introduced our AngioVue OCT Angiography imaging technology at the AAO in 2014,” said Jay Wei, founder and chief executive officer for Optovue. “Since that time, we have continued to pioneer new advancements to increase OCTA clinical utility and accessibility. Our recently introduced AngioVue Essential has been received with great enthusiasm by the market because it provides key information about retinal health in a format that busy general ophthalmology practices can interpret at a glance, thereby preserving the practice workflow.”
Initially announced in Sept. 2017, the AngioVue Essential provides fundamental OCTA features in a single-page report that displays individual layers of retinal vasculature alongside structural OCT B-scans. As a result, clinicians can quickly transform a basic eye exam into a comprehensive assessment of ocular health for each patient. This may provide peace-of-mind in high-risk or borderline cases, as well as improve the management and referral process of patients with ocular disease.
AAO attendees can see Optovue’s suite of advanced eye care products including the new AngioVue Essential OCTA capability in booth #3126. The book signings will take place on Nov. 11th at 4:00 pm in Optovue’s booth.
For the full, two-day schedule of the Interpretation Lab and a list of physicians leading each session, please click here.
Optovue, Inc. is a privately held medical device company founded in 2003. Headquartered in Fremont, Calif., the company is dedicated to the advancement and commercialization of high-speed OCT and OCTA technology used to facilitate the diagnosis and management of eye diseases, many of which may lead to permanent blindness. Optovue is the first company to develop and commercialize the pioneering OCTA technology. To date, there are over 350 peer-reviewed publications detailing the AngioVue Imaging technology and clinical applications, and well over 1,000 AngioVue systems installed. For more information, visit www.optovue.com.